We’re pleased to share that three new manuscripts in JACC Journals and one in #EHJ have been published with additional results from SEQUOIA-HCM, our pivotal Phase 3 clinical trial in #HCM. https://bit.ly/3XzjHD2
Cytokinetics
Biotechnology Research
South San Francisco, California 25,706 followers
Empowering Muscle Empowering Lives
About us
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
- Website
-
http://www.cytokinetics.com
External link for Cytokinetics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 1998
- Specialties
- Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
Locations
-
Primary
350 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Cytokinetics
-
Christopher Brey
Senior Director, Facilities and EHS
-
Brett Pletcher
Chief Legal Officer, Cytokinetics; Life Sciences and Public Company Advisor, Gunderson Dettmer; and Former General Counsel at Gilead Sciences
-
Stefan Engst
Principal Scientist at Cytokinetics
-
Kapil Menghrajani
Biopharmaceutical and Medical Diagnostic Professional
Updates
-
Over the weekend, we presented data from the Phase 1 study of CK-586 in a poster session at the the American College of Clinical Pharmacology® #2024ACCP Annual Meeting. Read more: https://bit.ly/4efUkLY
-
-
HeartBrothers Foundation is a recipient of our 2024 Communications Grant. The HeartBrothers will use this grant to expand outreach efforts, foster digital and in-person partnerships with heart failure hospitals nationwide, and increase overall awareness and information about patient resources. https://bit.ly/4gak0LF #heartfailureawareness
-
-
We're excited to highlight one of our 2024 Communications Grant recipients: WomenHeart: The National Coalition for Women with Heart Disease. Founded in 1999 by three women, WomenHeart will use this funding to raise awareness of women’s heart health by spotlighting powerful stories that inspire and empower women to take control of their heart health. https://bit.ly/3AL1t8m #hearthealth
-
-
Tomorrow we’re hosting an investor conference call to discuss the new data presented from SEQUOIA-HCM and FOREST-HCM. Join us at 8:00 AM ET: https://bit.ly/4g6qknr
-
-
Today we presented new data related to our investigational cardiac myosin inhibitor from SEQUOIA-HCM and FOREST-HCM in #HCM. Learn more here: https://bit.ly/4dLKp0z
-
-
Today we announced that we will participate in upcoming investor conferences hosted by Morgan Stanley, H.C. Wainwright & Co., LLC, & Cantor Fitzgerald. https://bit.ly/478lm5F
-
-
Cytokinetics is looking for talented, tenacious individuals to join us on our mission. We are powered by passion to make a difference for patients living with diseases in which muscle performance is compromised or declining. To learn more about how you could be empowered and make an impact with Cytokinetics, view our open positions and apply now! https://bit.ly/4bKRM6I #EmpoweredAtCytokinetics #hiring
-
-
As fall grows near, we want to give a heartfelt thank you to our 2024 summer interns! It was wonderful to have you at Cytokinetics, and we're excited to see where your careers take you! #internship2024 #interns
-
-
Last week, we were excited to partner with Denali Therapeutics and ALS Network to bring back the #SplashtoCureALS! Together, we helped raise awareness and funds for #ALS by dunking our CEO Robert Blum and EVP of Research and Development Fady Malik.
-